Abstract :

Over the past years, the use of medical cannabis is becoming of interest in the medical world. It has been recognized as an alternative treatment and has been legalized in many countries for medical purposes. Although there have been numerous claims of what cannabis can do, conclusive findings regarding its properties remain elusive. While access to cannabis is high, information accessible to consumers is still limited. Countless past studies have been done on cannabis’ effect on health issues. Hence, the purpose of this literature review was to conclude and summarize the past findings on the therapeutic effect of cannabis, focusing on the Delta-9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD), on the following medical conditions; chronic pain, opioid use disorder (OUD), obesity, sleep disorders, cancer, post-traumatic stress disorder (PTSD), psychosis, epilepsy, traumatic brain injury (TBI), Parkinson’s disease (PD), and Alzheimer’s disease. The risks of cannabis consumption for these issues were also identified. The results suggested that cannabis has the ability to assist in chronic pain, OUD, sleeping disorders, and Alzheimer’s disease. Regarding PTSD, psychosis, and TBI, there have been findings only about CBD which showed a beneficial effect on the diseases. It could not be concluded that cannabis can be used to treat obesity, cancer, epilepsy, and Parkinson’s disease due to limited evidence. The majority of the studies also demonstrated that high doses of CBD and low doses of THC should be used to maximize benefits. More clinical trials and research need to be conducted as there are research gaps and insufficient information in various subjects.

---

Keywords :

Cannabidiol, Cannabis, Delta-9-Tetrahydrocannabinol, Medical Conditions, Therapeutic Effect

---

References :

1. Rasera, G. B., Ohara, A., & de Castro, R. J. S. (2021). Innovative and emerging applications of cannabis in food and beverage products: From an illicit drug to a potential ingredient for health promotion. Trends in Food Science & Technology.
2. United Nations Office on Drugs, & Crime. (2009). Recommended Methods for the Identification and Analysis of Cannabis and Cannabis Products: Manual for Use by National Drug Testing Laboratories. United Nations Publications.
3. Farnsworth, N. R. (1969). Pharmacognosy and Chemistry of “Cannabis Sativa”. Journal of the American Pharmaceutical Association, 9(8), 410.
4. Small, E. (2015). Evolution and classification of Cannabis sativa (marijuana, hemp) in relation to human utilization. The botanical review, 81(3), 189-294.
5. Hill, R.J., (1983), Marijuana, Cannabis sativa L., Regulatory Horticulture, Weed Circular No. 5, 9 (1-2), 57-66.
6. Brenneisen, R. (2007). Chemistry and analysis of phytocannabinoids and other Cannabis constituents. In Marijuana and the Cannabinoids (pp. 17-49). Humana Press.
7. National Institute on Drug Abuse. (2021). What are marijuana’s effects?. Retrieved July 16, 2021 from https://drugabuse.gov/publications/research-reports/marijuana/what-are-marijuana-effects.
8. National Institute on Drug Abuse. (2021). How does marijuana produce its effects?. Retrieved June 16, 2021 from https://drugabuse.gov/publications/research-reports/marijuana/how-does-marijuana-produce-its-effects.
9. National Center for Biotechnology Information (2021). PubChem Compound Summary for CID 644019, Cannabidiol. Retrieved June 18, 2021 from https://pubchem.ncbi.nlm.nih.gov/compound/Cannabidiol.
10. World Health Organization. (2017). CANNABIDIOL (CBD) Pre-Review Report Agenda Item 5.2. Retrieved June 18, 2021 from https://who.int/medicines/access/controlled-substances/5.2_CBD.pdf.
11. Ameri, A. (1999). The effects of cannabinoids on the brain. Progress in neurobiology, 58(4), 315-348.
12. Atakan, Z. (2012). Cannabis, a complex plant: different compounds and different effects on individuals. Therapeutic advances in psychopharmacology, 2(6), 241-254.
13. Grotenhermen, F. (2005). Cannabinoids. Current Drug Targets-CNS & Neurological Disorders, 4(5), 507-530.
14. Shurtleff, D. (2018). Chronic Pain: In Depth. Retrieved June 18, 2021 from https://nccih.nih.gov/health/chronic-pain-in-depth.
15. Cirino, E. (2018). What Causes Chronic Pain? Retrieved June 18, 2021 from https://healthline.com/health/chronic-pain.
16. McAllister, M.P.J. (2019) Central Sensitization. Retrieved June 20, 2021 from
https://instituteforchronicpain.org/understanding-chronic-pain/what-is-chronic-pain/central-sensitization.
17. Mayo Clinic. (2021) Chronic pain: Medication decisions. Retrieved June 20, 2021 from https://mayoclinic.org/chronic-pain-medication-decisions/art-20360371.
18. Ho, K. Y., Gwee, K. A., Cheng, Y. K., Yoon, K. H., Hee, H. T., & Omar, A. R. (2018). Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice. Journal of pain research, 11, 1937–1948.
19. Ennis, Z.N., Dideriksen, D., Vægter, H.B., Handberg, G. and Pottegård, A. (2016), Acetaminophen for Chronic Pain: A Systematic Review on Efficacy. Basic Clin Pharmacol Toxicol, 118: 184-189.
20. Rosenblum, A., Marsch, L. A., Joseph, H., & Portenoy, R. K. (2008). Opioids and the treatment of chronic pain: controversies, current status, and future directions. Experimental and clinical psychopharmacology, 16(5), 405–416.
21. Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., & Kleijnen, J. (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA, 313(24), 2456–2473.
22. Yoko, M. (2021). IASP Position Statement on the Use of Cannabinoids to Treat Pain. Retrieved June 23, 2021 from

23. Argueta, D. A., Ventura, C. M., Kiven, S., Sagi, V., & Gupta, K. (2020). A Balanced Approach for Cannabidiol Use in Chronic Pain. Frontiers in pharmacology, 11, 561.
24. Gulbransen, G., Xu, W., & Arroll, B. (2020). Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand. BJGP open, 4(1), bjgpopen20X101010.
25. Providers Clinical Support System. (2021). Opioid Use Disorder: What is Opioid Addiction? – PCSS. Retrieved June 21, 2021 from https://pcssnow.org/resource/opioid-use-disorder-opioid-addiction/.
26. Saxon, A. (2020). Opioid Use Disorder. Retrieved June 23, 2021 from https://psychiatry.org/patients-families/addiction/opioid-use-disorder.
27. Dydyk A.M. (2021). Opioid Use Disorder – StatPearls – NCBI Bookshelf. Retrieved June 21, 2021 from
https://ncbi.nlm.nih.gov/books/NBK553166/.
28. The Substance Abuse and Mental Health Services Administration. (2021). Medication-Assisted Treatment (MAT). Retrieved June 23, 2021 from https://samhsa.gov/medication-assisted-treatment.
29. Recovery Research Institute. (2019). Study finds that cannabidiol (CBD) reduces drug craving and anxiety in patients recovering from heroin use disorder. Retrieved June 21, 2021 from https://recoveryanswers.org/research-post/cbd-effect-drug-craving-anxiety-heroin-use/.
30. Epstein, D. H., & Preston, K. L. (2015). No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper. The American journal on addictions, 24(4), 323–328.
31. Wiese, B., & Wilson-Poe, A. R. (2018). Emerging Evidence for Cannabis’ Role in Opioid Use Disorder. Cannabis and cannabinoid research, 3(1), 179–189.
32. Peachman, B.R.R. (2019). Can CBD Treat Opioid Addiction? Retrieved June 25, 2021 from
https://consumerreports.org/cbd/can-cbd-treat-opioid-addiction/.
33. Dugdale D.C. (2019). Health risks of obesity. Retrieved June 25, 2021 from
https://medlineplus.gov/ency/patientinstructions/000348.htm.
34. Mayo Clinic. (2020). Obesity – Symptoms and causes. Retrieved June 25, 2021 from
https://mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742.
35. Mayo Clinic. (2020). Obesity – Diagnosis and treatment – Mayo Clinic. Retrieved June 25, 2021 from
https://mayoclinic.org/diseases-conditions/obesity/diagnosis-treatment/drc-20375749.
36. National Institute of Diabetes and Digestive and Kidney Diseases. (2021). Prescription Medications to Treat Overweight & Obesity. Retrieved June 25, 2021 from
https://niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity.
37. University of Pittsburgh Medical Center. (2021). Bariatric Surgery Risks, Complications & Side Effects. Retrieved June 27, 2021 from https://upmc.com/services/bariatrics/candidate/risks-and-complications.
38. Yann Le Strat, Bernard Le Foll, Obesity and Cannabis Use: Results From 2 Representative National Surveys, American Journal of Epidemiology, Volume 174, Issue 8, 15 October 2011, Pages 929–933.
39. Le Foll, B., Trigo, J. M., Sharkey, K. A., & Le Strat, Y. (2013). Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss?. Medical hypotheses, 80(5), 564-567.
40. Pacheco D. (2021). Sleep Disorders. Retrieved June 27, 2021 from https://sleepfoundation.org/sleep-disorders.
41. Mayo Clinic. (2019). Sleep disorders – Symptoms and causes. Retrieved July 1, 2021 from
https://mayoclinic.org/diseases-conditions/sleep-disorders/symptoms-causes/syc-20354018.
42. Karna, B., & Gupta, V. (2020). Sleep Disorder. StatPearls. Retrieved July 1, 2021 from
https://ncbi.nlm.nih.gov/books/NBK560720/.
43. Sanford, A. E., Castillo, E., & Gannon, R. L. (2008). Cannabinoids and hamster circadian activity rhythms. Brain research, 1222, 141-148.
44. Vaughn, L. K., Denning, G., Stuhr, K. L., De Wit, H., Hill, M. N., & Hillard, C. J. (2010). Endocannabinoid signalling: has it got rhythm?. British journal of pharmacology, 160(3), 530-543.
45. Chagas, M. H., Crippa, J. A., Zuardi, A. W., Hallak, J. E., Machado-de-Sousa, J. P., Hirotsu, C., Maia, L., Tufik, S., & Andersen, M. L. (2013). Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. Journal of psychopharmacology (Oxford, England), 27(3), 312–316.
46. Hsiao, Y. T., Yi, P. L., Li, C. L., & Chang, F. C. (2012). Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats. Neuropharmacology, 62(1), 373-384.
47. Carley, D. W., Pavlovic, S., Janelidze, M., & Radulovacki, M. (2002). Functional role for cannabinoids in respiratory stability during sleep. Sleep, 25(4), 388-395.
48. Babson, K. A., Sottile, J., & Morabito, D. (2017). Cannabis, cannabinoids, and sleep: a review of the literature. Current psychiatry reports, 19(4), 1.
49. Vaughn, L. K., Denning, G., Stuhr, K. L., De Wit, H., Hill, M. N., & Hillard, C. J. (2010). Endocannabinoid signalling: has it got rhythm?. British journal of pharmacology, 160(3), 530-543.
50. Koch, M., Dehghani, F., Habazettl, I., Schomerus, C., & Korf, H. W. (2006). Cannabinoids attenuate norepinephrine‐induced melatonin biosynthesis in the rat pineal gland by reducing arylalkylamine N‐acetyltransferase activity without involvement of cannabinoid receptors. Journal of neurochemistry, 98(1), 267-278.
51. Murillo-Rodríguez E. (2008). The role of the CB1 receptor in the regulation of sleep. Progress in neuro-psychopharmacology & biological psychiatry, 32(6), 1420–1427.
52. National Cancer Institute. (2021). What Is Cancer? Retrieved July 6, 2021 from
https://cancer.gov/about-cancer/understanding/what-is-cancer.
53. American Cancer Society medical information. (2020). Signs and Symptoms of Cancer. Retrieved July 6, 2021 from
https://cancer.org/cancer/cancer-basics/signs-and-symptoms-of-cancer.html.
54. American Cancer Society medical information. (2020). Key Statistics for Soft Tissue Sarcomas. Retrieved July 6, 2021 from https://cancer.org/cancer/soft-tissue-sarcoma/about/key-statistics.html.
55. Cleveland Clinic medical professional. (2019), Leukemia: Symptoms, Types, Causes & Treatments. Retrieved July 6, 2021 from https://my.clevelandclinic.org/health/diseases/4365-leukemia.
56. Mayo Clinic. (2021). Lymphoma – Symptoms and causes. Retrieved July 6, 2021 from
https://mayoclinic.org/diseases-conditions/lymphoma/symptoms-causes/syc-20352638.
57. Tomasetti C. (2017). Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Retrieved July 8, 2021 from https://science.sciencemag.org/content/355/6331/1330.abstract.
58. Mayo Clinic. (2020). Chemotherapy. Retrieved July 8, 2021 from
https://mayoclinic.org/tests-procedures/chemotherapy/about/pac-20385033.
59. Prostate Cancer UK. (2019). Side effects of hormone therapy. Retrieved July 8, 2021 from
https://prostatecanceruk.org/prostate-information/living-with-prostate-cancer/how-hormone-therapy-affects-you.
60. National Cancer Institute. (2019). Side Effects of Immunotherapy. Retrieved July 8, 2021 from
https://cancer.gov/about-cancer/treatment/types/immunotherapy/side-effects.
61. National Cancer Institute. (2019). Radiation Therapy for Cancer. Retrieved July 8, 2021 from
https://cancer.gov/about-cancer/treatment/types/radiation-therapy.
62. Tohme S. (2017). Surgery for Cancer: A Trigger for Metastases. Retrieved July 11, 2021 from
https://cancerres.aacrjournals.org/content/77/7/1548.short.
63. Cancer.Net. (2021). Understanding Targeted Therapy. Retrieved July 11, 2021 from
https://cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/understanding-targeted-therapy.
64. American Cancer Society medical information. (2020). Targeted Therapy Side Effects. Retrieved July 11, 2021 from
https://cancer.org/treatment/treatments-and-side-effects/treatment-types/targeted-therapy/side-effects.html.
65. Bar-Lev Schleider, L., Mechoulam, R., Lederman, V., Hilou, M., Lencovsky, O., Betzalel, O., Shbiro, L., & Novack, V. (2018). Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. European journal of internal medicine, 49, 37–43.
66. Seltzer, E. S., Watters, A. K., MacKenzie, D., Jr, Granat, L. M., & Zhang, D. (2020). Cannabidiol (CBD) as a Promising Anti-Cancer Drug. Cancers, 12(11), 3203.
67. Gurney, J., Shaw, C., Stanley, J., Signal, V., & Sarfati, D. (2015). Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. BMC cancer, 15, 897.
68. National Institute of Mental Health. (2019). Post-Traumatic Stress Disorder. Retrieved July 11, 2021 from
https://nimh.nih.gov/health/topics/post-traumatic-stress-disorder-ptsd.
69. NHS website. (2021). Causes – Post-traumatic stress disorder. Retrieved July 11, 2021 from
https://nhs.uk/mental-health/conditions/post-traumatic-stress-disorder-ptsd/causes/.
70. American Psychological Association. (2020). PTSD Treatments. Retrieved July 11, 2021 from
https://apa.org/ptsd-guideline/treatments.
71. American Psychological Association. (2020). Prolonged Exposure (PE). Retrieved July 11, 2021 from
https://apa.org/ptsd-guideline/treatments/prolonged-exposure.
72. Cruz J.S. (2020). Cannabis in the Treatment of PTSD. Retrieved July 11, 2021 from
https://crxmag.com/issues/2020/spring/cannabis-in-the-treatment-of-ptsd.shtml#.
73. Drnatmed Medical Marijuana Card Colorado. (2021). Medical Marijuana Treatment for PTSD – Cannabis PTSD. Retrieved July 11, 2021 from https://drnatmed.com/medical-marijuana-for-ptsd/.
74. National Institutes of Health (2020). NIMH » Understanding Psychosis.Retrieved July 11, 2021 from
https://nimh.nih.gov/health/publications/understanding-psychosis.
75. Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimarães FS. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des. 2012;18(32):5131-40.
76. Degenhardt L, Hall W. Is Cannabis Use a Contributory Cause of Psychosis? The Canadian Journal of Psychiatry. 2006;51(9):556-565.
77. Schubart, C. D., Sommer, I. E. C., Fusar-Poli, P., De Witte, L., Kahn, R. S., & Boks, M. P. M. (2014). Cannabidiol as a potential treatment for psychosis. European Neuropsychopharmacology, 24(1), 51-64.
78. Sewell, R. A., Ranganathan, M., & D’Souza, D. C. (2009). Cannabinoids and psychosis. International Review of Psychiatry, 21(2), 152-162.
79. Moshé, S. L., Perucca, E., Ryvlin, P., & Tomson, T. (2015). Epilepsy: new advances. The Lancet, 385(9971), 884-898.
80. Duncan, J. S., Sander, J. W., Sisodiya, S. M., & Walker, M. C. (2006). Adult epilepsy. The Lancet, 367(9516), 1087-1100.
81. Perucca, E., & Tomson, T. (2011). The pharmacological treatment of epilepsy in adults. The Lancet neurology, 10(5), 446-456.
82. Schmidt, D. (2009). Drug treatment of epilepsy: options and limitations. Epilepsy & behavior, 15(1), 56-65.
83. Cascino, G. D. (2004). Surgical treatment for epilepsy. Epilepsy research, 60(2-3), 179-186.
84. Miller, J. W., & Hakimian, S. (2013). Surgical treatment of epilepsy. Continuum: Lifelong Learning in Neurology, 19(3 Epilepsy), 730.
85. Gaston, T. E., & Szaflarski, J. P. (2018). Cannabis for the treatment of epilepsy: an update. Current neurology and neuroscience reports, 18(11), 1-9.
86. Devinsky, O., Cilio, M. R., Cross, H., Fernandez-Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras-Aswad, D., Notcutt, W. G., Martinez-Orgado, J., Robson, P. J., Rohrback, B. G., Thiele, E., Whalley, B., & Friedman, D. (2014). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55(6), 791–802.
87. Parikh, S., Koch, M., & Narayan, R. K. (2007). Traumatic brain injury. International anesthesiology clinics, 45(3), 119-135.
88. Saatman, K. E., Duhaime, A. C., Bullock, R., Maas, A. I., Valadka, A., & Manley, G. T. (2008). Classification of traumatic brain injury for targeted therapies. Journal of neurotrauma, 25(7), 719-738.
89. Iaccarino, C., Carretta, A., Nicolosi, F., & Morselli, C. (2018). Epidemiology of severe traumatic brain injury. Journal of neurosurgical sciences, 62(5), 535-541.
90. Hergert, D. C., Robertson-Benta, C., Sicard, V., Schwotzer, D., Hutchison, K., Covey, D. P., … & Mayer, A. R. (2021). Use of medical cannabis to treat traumatic brain injury. Journal of neurotrauma, 38(14), 1904–1917.
91. Belardo, C., Iannotta, M., Boccella, S., Rubino, R. C., Ricciardi, F., Infantino, R., … & Guida, F. (2019). Oral cannabidiol prevents allodynia and neurological dysfunctions in a mouse model of mild traumatic brain injury. Frontiers in pharmacology, 10, 352.
92. Schurman, L. D., & Lichtman, A. H. (2017). Endocannabinoids: a promising impact for traumatic brain injury. Frontiers in pharmacology, 8, 69.
93. De Lau, L. M., & Breteler, M. M. (2006). Epidemiology of Parkinson’s disease. The Lancet Neurology, 5(6), 525-535.
94. Lill, C. M., & Klein, C. (2017). Epidemiology and causes of Parkinson’s disease. Der Nervenarzt, 88(4), 345-355.
95. Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and Treatment of Parkinson Disease: A Review. JAMA, 323(6), 548–560.
96. Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020). Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease. Frontiers in pharmacology, 11, 595635.
97. Singh, N., Pillay, V., & Choonara, Y. E. (2007). Advances in the treatment of Parkinson’s disease. Progress in neurobiology, 81(1), 29-44.
98. Kindred, J. H., Li, K., Ketelhut, N. B., Proessl, F., Fling, B. W., Honce, J. M., … & Rudroff, T. (2017). Cannabis use in people with Parkinson’s disease and Multiple Sclerosis: A web-based investigation. Complementary therapies in medicine, 33, 99-104.
99. Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020). Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease. Frontiers in pharmacology, 11, 595635.
100. HH Patel, M.Pharm. (2019) Types of Alzheimer’s Disease. Retrieved July 11, 2021 from
https://news-medical.net/health/Types-of-Alzheimers-Disease.aspx.
101. Lyketsos C. G. (2020). Treatment Development for Alzheimer’s Disease: How Are We Doing?. Advances in experimental medicine and biology, 1195, 19.
102. Munoz, D. G., & Feldman, H. (2000). Causes of Alzheimer’s disease. Cmaj, 162(1), 65-72.
103. Brewer G. J. (2009). The risks of copper toxicity contributing to cognitive decline in the aging population and to Alzheimer’s disease. Journal of the American College of Nutrition, 28(3), 238–242.
104. Schelterns, P., & Feldman, H. (2003). Treatment of Alzheimer’s disease; current status and new perspectives. The Lancet Neurology, 2(9), 539-547.
105. Watt, G., & Karl, T. (2017). In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s Disease. Frontiers in pharmacology, 8, 20.
106. Li, H., Liu, Y., Tian, D., Tian, L., Ju, X., Qi, L., … & Liang, C. (2020). Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer’s disease. European journal of medicinal chemistry, 192, 112163.